Response assessment with the CXCR4-directed positron emission tomography tracer 68GaPentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavitiesReportar como inadecuado




Response assessment with the CXCR4-directed positron emission tomography tracer 68GaPentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

EJNMMI Research

, 7:51

First Online: 02 June 2017Received: 06 March 2017Accepted: 17 May 2017DOI: 10.1186-s13550-017-0294-z

Cite this article as: Herhaus, P., Habringer, S., Vag, T. et al. EJNMMI Res 2017 7: 51. doi:10.1186-s13550-017-0294-z

Abstract

CXCR4 belongs to the family of chemokine receptors. Together with its sole known ligand CXCL12 SDF-1alpha, it has a pivotal role during organogenesis and for homing of hematopoietic stem cells. CXCR4 is overexpressed in various malignancies, and this is often associated with poor prognosis. Therefore, molecular imaging of CXCR4 bears a great potential for diagnostics and selecting patients for CXCR4-directed therapies. The CXCR4-directed positron emission tomography PET tracer GaPentixafor has been shown to visualize CXCR4 expression in various malignancies in vivo. Whereas this tracer has limitations compared to F-Fluorodeoxyglucose FFDG in diagnostic PET imaging in peripheral tumour lesions, it might add valuable information in routine diagnostics and response assessment of tumours in close proximity to the central nervous system CNS and malignancies within this organ. As a proof-of-concept, we performed GaPentixafor PET imaging in a patient with extranodal marginal zone lymphoma MZL of the orbital cavities at diagnosis and for post-therapy response assessment. Compared to routinely conducted FFDG PET, the lymphoma lesions determined by magnetic resonance imaging MRI showed high tracer accumulation at diagnosis, which decreased upon treatment. We therefore propose that imaging of CXCR4 with GaPentixafor is a potential diagnostic tool for tumours close to or within the CNS and suggest this being studied in clinical trials.

KeywordsChemokine receptor CXCR4 Lymphoma GaPentixafor PET Response assessment AbbreviationsFFDGF-Fluorodeoxyglucose

CNSCentral nervous system

MALTMucosa-associated lymphoid tissue

MRIMagnetic resonance imaging

MZLMarginal zone lymphoma

PETPositron emission tomography

PRRTPeptide-receptor radiotherapy

SDF-1αStromal cell-derived factor-1alpha

SUVStandardized uptake value

TTBTumour-to-background ratio

Download fulltext PDF



Autor: Peter Herhaus - Stefan Habringer - Tibor Vag - Katja Steiger - Julia Slotta-Huspenina - Carlos Gerngroß - Benedikt Wiestle

Fuente: https://link.springer.com/







Documentos relacionados